Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
2.
Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
5.
Report provides global picture of wide inequalities in care for women's cancers
1.
The Benefits and Risks of Transurethral Resection of Bladder Tumor
2.
Cold Antibody AIHA and Neoplastic Disorders: Unraveling the Clinical and Pathogenic Link
3.
From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma
4.
Unlocking the Mystery of Methaemoglobinaemia: A New Hope for Treatment
5.
Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge